Lindsey Bull
Optometrist · Tulsa, OKNPI 1700132024
Payments from drug & device makers
Across 779 payments — averaging $280.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$196K
- Kala Pharmaceuticals, Inc.$15K
- Biotissue Holdings Inc.$2K
- Oyster Point Pharma, Inc.$2K
- Novartis$571
- Tarsus Pharmaceuticals, Inc.$561
- plus $2K from 15 others
What the payments were for
- Consulting fees$24,88011%
- Speaking & faculty fees$142,73165%
- Travel & lodging$37,11917%
- Food & beverage$13,4746%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 560 | $196,222 |
| Kala Pharmaceuticals, Inc. | 50 | $15,084 |
| Biotissue Holdings Inc. | 9 | $1,908 |
| Oyster Point Pharma, Inc. | 18 | $1,779 |
| Novartis | 34 | $571 |
| Tarsus Pharmaceuticals, Inc. | 23 | $561 |
| Sun Pharmaceutical Industries Inc. | 27 | $510 |
| Alcon | 7 | $308 |
| ANI Pharmaceuticals, Inc. | 8 | $259 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 11 | $234 |
| Dompe US, Inc. | 5 | $232 |
| Shire North American Group Inc | 9 | $126 |
| Amgen(2 entities) | 6 | $113 |
| Mallinckrodt Hospital Products Inc. | 1 | $100 |
| Mallinckrodt Enterprises LLC | 1 | $80 |
| Bausch & Lomb Americas Inc. | 4 | $79 |
| Glaukos Corporation | 1 | $40 |
| Harrow Eye, LLC | 2 | $35 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $21 |
| Aerie Pharmaceuticals, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VUITY$104,339
- RESTASIS MULTIDOSE$42,851
- LUMIGAN$35,577
- EYSUVIS$14,499
- RESTASIS$12,463
- ALPHAGAN P$4,781
- COMBIGAN$4,331
- INVELTYS$2,957
- TYRVAYA$1,547
- Prokera$1,509
- AmnioGraft$1,509
- Clareon PanOptix Pro$150
- XDEMVY$120
- Oxervate$115
- AcrySof IQ VIVITY IOL$109
How this compares
$218,304 in reported general payments places this provider in the 95th percentile of 714 optometrist providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 254 | $242,342 |
| LumiganBimatoprost | 321 | $180,353 |
| XdemvyLotilaner | 25 | $48,779 |
| CombiganBrimonidine Tartrate/Timolol | 85 | $35,590 |
| TyrvayaVarenicline Tartrate | 18 | $18,368 |
| XiidraLifitegrast | 11 | $12,679 |
| Alphagan PBrimonidine Tartrate | 22 | $9,788 |
| CequaCyclosporine | 11 | $9,473 |
| Prednisolone Acetate | 272 | $9,043 |
| VyzultaLatanoprostene Bunod | 14 | $7,634 |
| ProlensaBromfenac Sodium | 16 | $5,625 |
| Travatan ZTravoprost | 11 | $5,278 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 20 | $4,755 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 23 | $4,548 |
| Latanoprost | 196 | $3,361 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $196,222 | $468,073682 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $561 | $48,77925 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $79 | $20,31325 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $1,779 | $18,36818 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $510 | $9,47311 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $234 | $5,62516 claims |
| NovartisTravatan Z | $571 | $5,27811 claims |
| AlconSimbrinza | $308 | $4,75520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 714 optometrist providers in Oklahoma.
Other optometrist in Tulsa
- Wesley DerosierTulsa$48K
- Brian WilliamsTulsa$9K
- Lynsey BigheartTulsa$9K
- Shannon MorgansTulsa$8K
- Blane SnodgrassTulsa$7K
- Brett BeasleyTulsa$6K
- Travis PartinTulsa$6K
- Christopher McDanielsTulsa$5K
- Terry LawsonTulsa$4K
- Selina McGeeEdmond$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.